- Home
- HURA
as 12-20-2024 1:37pm EST
Stocks
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | TAMPA |
| Market Cap: | 246.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 668.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.83 - $14.60 | Next Earning Date: | 02-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest TuHURA Biosciences Inc. Common Stock News
HURA Breaking Stock News: Dive into HURA Ticker-Specific Updates for Smart Investing
ACCESSWIRE
10 days ago
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
ACCESSWIRE
a month ago
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
ACCESSWIRE
2 months ago
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
ACCESSWIRE
2 months ago
TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event
Compare HURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HURA TuHURA Biosciences Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.